Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers—reply

We thank Dr. Wu and colleagues for their interest in our manuscript on expression of histone deacetylases (HDACs) in pancreatic neuroendocrine tumors (pNET) [1] and for expressing further thoughts on HDACs as potential diagnostic and pharmacological inhibitors and as therapeutic targets for specific cancer types. We appreciate the opportunity to reply and further explain some of our observations.

http://ift.tt/2gtJXce